Uli Stilz, PhD

Uli Stilz is Head of the Novo Nordisk Bio Innovation Hub Transformative Research Unit (TRU) in Boston. In this role, he is leading a cross functional R&D team developing innovative partnership models with biotech, venture capital, and academia to co-create novel therapies and technologies to provide life changing treatments for people living with cardiometabolic and rare diseases.

Uli Stilz graduated with a Master degree in Organic Chemistry from ETH Zürich. He then moved to the Max-Planck-Institute of Biochemistry in Martinsried, where he received his Ph.D. in 1990.

After postdoctoral studies at the California Institute of Technology he joined Hoechst AG were he held various positions before he was appointed Associate Vice President of the newly established Innovation unit within the Diabetes Division at Sanofi in 2010. Over a period of 20 years, he contributed to more than 60 preclinical and clinical drug candidates across cardiometabolic, immunology, and oncology therapy areas. Between 2012 and 2014 he was President of the European Federation for Medicinal Chemistry.

In 2014, Uli joined Novo Nordisk A/S in Copenhagen and in 2019 relocated to Boston to create and lead the Novo Nordisk Bio Innovation Hub TRU which was established in 2021.

Uli Stilz was appointed adjunct professor at the University of Frankfurt in 2012 and serves on Editorial Boards for international peer-reviewed journals. He is a member of several Scientific Advisory Boards in North America and Europe, and has represented Novo Nordisk A/S at trade organizations (EFPIA).
Speaking In
11:00 AM - 12:00 PM
Wednesday, June 7
The pandemic forced support ecosystems for emerging biotechs to adapt their processes to continue…